NUT midline carcinoma presenting initially as thyroid cancer: a case report and review of treatment

Abstract

The purpose of this abstract is to provide data on a 27-year-old woman with a rare and rapidly progressive cancer, Nuclear in Testis (NUT) carcinoma (NC), and to highlight possible treatment options for her specific gene translocation of NSD3-NUT. To our knowledge, this is the first case in the literature that was presented initially as anaplastic thyroid cancer. We propose that targeted therapy with a histone lysine methyltransferase inhibitor may be of benefit as adjunctive therapy in patients with the NSD3-NUT gene translocation.

Keywords

Nuclear in Testis (NUT) carcinoma / NUT midline carcinoma / NUT midline carcinoma thyroid / NUT midline carcinoma BET / NUT midline carcinoma histone methyltransferase / NUT-midline immune checkpoint inhibitors / NUT midline treatment

References

[1] Greco FA.Introduction: unknown primary cancer.Semin Oncol2009;36:6-7

[2] Available from: https://www.cancer.org/content/dam/CRC/PDF/Public/8589.00.pdf [Last accessed on 24 Jun 2022].

[3] Jiang J,Xu C.NUT midline carcinoma as a primary lung tumor treated with anlotinib combined with palliative radiotherapy: a case report.Diagn Pathol2022;17:4 PMCID:PMC8742416

[4] McEvoy CR,Prall OWJ.Emerging entities in NUTM1-rearranged neoplasms.Genes Chromosomes Cancer2020;59:375-85

[5] Kim YH,Kim JK.False-negative errors in next-generation sequencing contribute substantially to inconsistency of mutation databases.PLoS One2019;14:e0222535 PMCID:PMC6742382

[6] Kubonishi I,Iwata J.Novel t(15;19) chromosome abnormality in a thymic carcinoma.Cancer Res1991;51:3327-8

[7] Bauer DE,Strait KM.Clinicopathologic features and long-term outcomes of NUT midline carcinoma.Clin Cancer Res2012;18:5773-9 PMCID:PMC3473162

[8] Chau NG,Danga K.An anatomical site and genetic-based prognostic model for patients with nuclear protein in testis (NUT) midline carcinoma: analysis of 124 patients.JNCI Cancer Spectr2020;4:pkz094 PMCID:PMC7165803

[9] Available from: https://nmcregistry.org/ [Last accessed on 24 Jun 2022].

[10] Huang QW,Zheng S,Peng BN.An overview of molecular mechanism, clinicopathological factors, and treatment in nut carcinoma.Biomed Res Int2019;2019:1018439 PMCID:PMC6877965

[11] Prall OWJ,Yerneni S,McEvoy CR.A NUT carcinoma lacking squamous differentiation and expressing TTF1.Pathology2021;53:663-6

[12] Brägelmann J,Dietlein F.Systematic kinase inhibitor profiling identifies CDK9 as a synthetic lethal target in NUT midline carcinoma.Cell Rep2017;20:2833-45 PMCID:PMC5622049

[13] Han X,Zhuang Q,Liu Z.The role of histone lysine methyltransferase NSD3 in cancer.Onco Targets Ther2018;11:3847-52 PMCID:PMC6038882

[14] Agaimy A,Stoehr R.NSD3-NUTM1-rearranged carcinoma of the median neck/thyroid bed developing after recent thyroidectomy for sclerosing mucoepidermoid carcinoma with eosinophilia: report of an extraordinary case.Virchows Arch2021;479:1095-9 PMCID:PMC8724182

[15] Landa I,Boucai L.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.J Clin Invest2016;126:1052-66 PMCID:PMC4767360

[16] Zhou J,Jiao Q.Primary thyroid NUT carcinoma with high PD-L1 expression and novel massive.IGKV11:778296 PMCID:PMC8807656

[17] Allison DB,Cornea V,Dueber J.Thyroid carcinoma with NSD3::NUTM1 fusion: a case with thyrocyte differentiation and colloid production.Endocr Pathol2022;33:315-26

[18] Chau NG,Mitchell CM.Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck.Cancer2016;122:3632-40 PMCID:PMC5361614

[19] Lim SL,Han BC,Chng WJ.Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor.PLoS One2020;15:e0232068 PMCID:PMC7304913

[20] Jung M,Lee JK.Clinicopathological and preclinical findings of NUT carcinoma: a multicenter study.Oncologist2019;24:e740-8 PMCID:PMC6693698

[21] Zhao C,Xu Q.Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present).Expert Opin Ther Pat2020;30:263-74

[22] Shiota H,Wang ZA.Chemical screen identifies diverse and novel histone deacetylase inhibitors as repressors of NUT function: implications for NUT carcinoma pathogenesis and treatment.Mol Cancer Res2021;19:1818-30. PMCID:PMC8568634

[23] French CA.Pathogenesis of NUT midline carcinoma.Annu Rev Pathol2012;7:247-65

[24] Napolitano M,Molinaro E.NUT midline carcinoma of the head and neck: current perspectives.Onco Targets Ther2019;12:3235-44 PMCID:PMC6501778

[25] Grayson AR,Cameron MJ.MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma.Oncogene2013;33:1736-42. PMCID:PMC3942361

[26] Piha-Paul SA,French CA.Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors.JNCI Cancer Spectr2020;4:pkz093 PMCID:PMC7165800

[27] Lewin J,Stathis A.Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors.J Clin Oncol2018;36:3007-14

[28] Stathis A,Bekradda M.Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015/MK-8628.Cancer Discov2016;6:492-500 PMCID:PMC4854801

[29] Liao S,Cichowski K.Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is.Genes Dev2018;32:1188-200 PMCID:PMC6120715

[30] Hogg SJ,Deswal S.BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1.Cell Rep2017;18:2162-74 PMCID:PMC5340981

[31] Xie XH,Qin YY.Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma.Orphanet J Rare Dis2020;15:183 PMCID:PMC7350189